<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328873</url>
  </required_header>
  <id_info>
    <org_study_id>NSH 909</org_study_id>
    <nct_id>NCT01328873</nct_id>
  </id_info>
  <brief_title>FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates</brief_title>
  <official_title>A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction With FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood and Marrow Transplant Group of Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary infiltrates frequently complicate the care of hematopoietic stem cell transplant
      (HSCT) and leukemia patients. Bronchoalveolar lavage (BAL) is frequently used to evaluate new
      pulmonary infiltrates in this population, however utility is limited by a historically low
      diagnostic yield for infection.

      In an effort to improve diagnostic yields, this study will complete a Fiberoptic Bronchoscopy
      (FOB) within 8 hours of radiographic documentation of pulmonary infiltrates, prior to
      initiating new antibiotic therapy. To further improve detection of microbiological pathogens,
      the study will utilize PCR testing with rapid turnaround time to detect atypical pneumonia (M
      pneumoniae, C. Pneumonia, Legionella species, and respiratory viruses) and aspergillosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proper diagnosis and prompt treatment favorably impacts survival in the post transplant
      setting, but is often difficult and frequently results in inappropriate or late therapy. Low
      yields may be linked with empiric antibody therapy begun prior to the procedure, delayed time
      to procedure, procedure technique, the presence of graft versus host disease (GVHD),
      neutropenia, and diffuse infiltrates (as opposed to localized infiltrates or focal masses and
      nodules). One recent study found that early FOBs (less than or equal to 4 days between
      detection of pulmonary infiltrates and FOB) were 2.5 times more likely to establish a
      diagnosis of pneumonia compared to late examinations. Delaying this procedure(greater than 5
      days between detection of pulmonary infiltrates and FOB) was associated with drug resistant
      organisms, polymicrobial infections, and worsened patient prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Positive Culture or Molecular Results After Brochoscopy</measure>
    <time_frame>30 days</time_frame>
    <description>To determine the diagnostic yield related to fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) in hematopoietic stem cell transplant (HSCT) and leukemia patients with acute respiratory symptoms and pulmonary infiltrates utilizing both current standard of care microbiology testing and emerging molecular genetic laboratory assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Positive CT Result</measure>
    <time_frame>30 days</time_frame>
    <description>To correlate specific types of pulmonary infiltrates (focal, multifocal, or diffuse interstitial or alveolar infiltrates) with microbiological findings. Patients were evaluated by changes on the CT and categorized as follows:
Air space
ground glass/reticular nodular
nodular/cavitary
single patchy infiltrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Bacterial Results by PCR</measure>
    <time_frame>24-48 hours</time_frame>
    <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Positive Fungal Results by PCR</measure>
    <time_frame>24-48 hours</time_frame>
    <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Viral Results by PCR</measure>
    <time_frame>24-48 hours</time_frame>
    <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Myocbacteria Results by Culture</measure>
    <time_frame>24-48 hours</time_frame>
    <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Pulmonary Infiltrate New</condition>
  <arm_group>
    <arm_group_label>Laboratory testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive the lab testing on bronchoscopy specimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microbiological analysis</intervention_name>
    <description>Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
    <arm_group_label>Laboratory testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autologous or allogeneic stem cell patients with new acute respiratory symptoms or
             pulmonary infiltrates

          -  leukemia patients with new acute respiratory symptoms or pulmonary infiltrates thought
             to be unrelated to disease

        Exclusion Criteria:

          -  Patients unwilling to undergo FOB

          -  Patients unable to undergo FOB due to clinical status

          -  Patients unable to undergo FOB within 8 hours of radiographic report of pneumonia

          -  Patients unable to wait until completion of FOB to implement antibiotic changes

          -  Adults unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Kent Holland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Apr;45(4):647-55. doi: 10.1038/bmt.2009.203. Epub 2009 Aug 17.</citation>
    <PMID>19684637</PMID>
  </reference>
  <reference>
    <citation>Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72.</citation>
    <PMID>17278083</PMID>
  </reference>
  <reference>
    <citation>Hardak E, Yigla M, Avivi I, Fruchter O, Sprecher H, Oren I. Impact of PCR-based diagnosis of invasive pulmonary aspergillosis on clinical outcome. Bone Marrow Transplant. 2009 Nov;44(9):595-9. doi: 10.1038/bmt.2009.65. Epub 2009 Mar 23.</citation>
    <PMID>19308034</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <results_first_submitted>October 5, 2016</results_first_submitted>
  <results_first_submitted_qc>March 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2017</results_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary infiltrates</keyword>
  <keyword>stem cell transplant</keyword>
  <keyword>leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Signs and Symptoms, Respiratory</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period - May 2011 - Sept 2015 Patients were identified in either the outpatient clinic or inpatient BMT/Leukemia unit</recruitment_details>
      <pre_assignment_details>Patients were excluded only if they refused to participate or required antibiotic changes within the 7 days prior to being approached for the study. An additional 2 pateints were considered screen failures for this study and did not proceed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Laboratory Testing</title>
          <description>All patients will receive the lab testing on bronchoscopy specimens
Microbiological analysis: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laboratory Testing</title>
          <description>All patients will receive the lab testing on bronchoscopy specimens
Microbiological analysis: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Patients were treated in an adult center. All patients were over the age of 18.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Positive Culture or Molecular Results After Brochoscopy</title>
        <description>To determine the diagnostic yield related to fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) in hematopoietic stem cell transplant (HSCT) and leukemia patients with acute respiratory symptoms and pulmonary infiltrates utilizing both current standard of care microbiology testing and emerging molecular genetic laboratory assessments.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Will Receive Lab Testing on Bronchoscopy Specimen</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Positive Culture or Molecular Results After Brochoscopy</title>
          <description>To determine the diagnostic yield related to fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) in hematopoietic stem cell transplant (HSCT) and leukemia patients with acute respiratory symptoms and pulmonary infiltrates utilizing both current standard of care microbiology testing and emerging molecular genetic laboratory assessments.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Positive CT Result</title>
        <description>To correlate specific types of pulmonary infiltrates (focal, multifocal, or diffuse interstitial or alveolar infiltrates) with microbiological findings. Patients were evaluated by changes on the CT and categorized as follows:
Air space
ground glass/reticular nodular
nodular/cavitary
single patchy infiltrate</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laboratory Testing</title>
            <description>Patients were evaluated by changes on the CT and categorized as follows:
Air space
ground glass/reticular nodular
nodular/cavitary
single patchy infiltrate
These were evaluated on CT scans and all units of measure are the same.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Positive CT Result</title>
          <description>To correlate specific types of pulmonary infiltrates (focal, multifocal, or diffuse interstitial or alveolar infiltrates) with microbiological findings. Patients were evaluated by changes on the CT and categorized as follows:
Air space
ground glass/reticular nodular
nodular/cavitary
single patchy infiltrate</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Bacterial Results by PCR</title>
        <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
        <time_frame>24-48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laboratory Testing</title>
            <description>All patients will receive the lab testing on bronchoscopy specimens
Microbiological analysis: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Bacterial Results by PCR</title>
          <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Positive Fungal Results by PCR</title>
        <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
        <time_frame>24-48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laboratory Testing</title>
            <description>All patients will receive the lab testing on bronchoscopy specimens
Microbiological analysis: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Positive Fungal Results by PCR</title>
          <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Viral Results by PCR</title>
        <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
        <time_frame>24-48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laboratory Testing</title>
            <description>All patients will receive the lab testing on bronchoscopy specimens
Microbiological analysis: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Viral Results by PCR</title>
          <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Myocbacteria Results by Culture</title>
        <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
        <time_frame>24-48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laboratory Testing</title>
            <description>All patients will receive the lab testing on bronchoscopy specimens
Microbiological analysis: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Myocbacteria Results by Culture</title>
          <description>To describe the microbiological findings in HSCT and leukemia patients with fever, respiratory symptoms, and pulmonary infiltrates</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Laboratory Testing</title>
          <description>All patients will receive the lab testing on bronchoscopy specimens
Microbiological analysis: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publications will need prior written consent from sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Kent Holland, MD</name_or_title>
      <organization>Northside Hospital</organization>
      <phone>404-255-1930</phone>
      <email>kholland@bmtga.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

